BMSSC
IMVT icon

B. Metzler seel. Sohn & Co’s Immunovant IMVT Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,136
Closed -$310K – 739
2025
Q1 		$310K Hold
18,136
– – ﹤0.01% 688
2024
Q4 		$449K Hold
18,136
– – ﹤0.01% 659
2024
Q3 		$517K Hold
18,136
– – 0.01% 639
2024
Q2 		$479K Hold
18,136
– – ﹤0.01% 641
2024
Q1 		$586K Hold
18,136
– – 0.01% 598
2023
Q4 		$764K Buy
+18,136
New +$667K 0.01% 542

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

B. Metzler seel. Sohn & Co's IMVT Position: Q2 2025 in Review

B. Metzler seel. Sohn & Co sold out of Immunovant (IMVT) in Q2 2025, closing a stake of 18,136 shares — an estimated $310K sold.

B. Metzler seel. Sohn & Co first reported a position in IMVT in Q4 2023 and held it in 6 quarters. The position peaked at $764K in Q4 2023. 168 funds tracked by Wall St. Rank hold IMVT as of Q2 2025.

  • B. Metzler seel. Sohn & Co reported no remaining Immunovant position as of Q2 2025 after selling out during the quarter.
  • B. Metzler seel. Sohn & Co sold 18,136 Immunovant shares in Q2 2025, an estimated $310K.
  • B. Metzler seel. Sohn & Co first reported a position in Immunovant in Q4 2023 and held it in 6 quarters.
  • B. Metzler seel. Sohn & Co's Immunovant position peaked at $764K in Q4 2023.
  • 168 funds tracked by Wall St. Rank held Immunovant as of Q2 2025.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q2 2025, filed 11 Aug 2025.